FAIRFIELD, N.J., Feb. 27 /PRNewswire-FirstCall/ -- BRADLEY
PHARMACEUTICALS, INC. (NYSE: BDY) today announced that Daniel Glassman,
President and CEO, will speak to investors and analysts attending the Raymond
James 25th Annual Institutional Investors Conference, to be held at the Hyatt
Grand Cypress in Orlando, FL, February 29-March 3, 2004.
To listen to a live audio Webcast of the Bradley presentation on Monday,
March 1, 2004 at 11:00 A.M. EST, go to:
http://www.wallstreetwebcasting.com/webcast/rjii04
Login: event
Password: viewer
Listeners should access this site at least 15 minutes prior to the event
to register and download any necessary software. Pre-registration is currently
available. A replay of the presentation will be available for 30 days
following the conference, and can be accessed at:
http://www.wallstreetwebcasting.com/webcast/rjii04/bdy
Bradley Pharmaceuticals, Inc., a publicly traded company, was founded in
1985 as a specialty pharmaceutical company marketing to niche physician
specialties in the US and 38 international markets. Bradley's success revolves
around the strategy of Acquire, Enhance and Grow. Bradley Acquires non-
strategic brands, Enhances these brands with line extensions and improved
formulations and Grows the products through promotion, advertising and selling
activities to optimize life cycle management. Bradley Pharmaceuticals has two
operating units: Doak Dermatologics, specializing in topical therapies for
dermatology and podiatry, and Kenwood Therapeutics, providing
gastroenterology, respiratory and other internal medicine brands.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the
symbol BDY.
Except for historical and factual information, this press release contains
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements include
statements that address activities, events or developments that Bradley
expects, believes or anticipates will or may occur in the future, such as
earnings estimates, launches of new products, market acceptance of products,
and predictions of future financial performance. All forward-looking
statements are based on assumptions made by Bradley based on its experience
and perception of historical trends, current conditions, expected future
developments and other factors it believes are appropriate under the
circumstances. These statements are subject to numerous risks and
uncertainties, many of which are beyond Bradley's control, including Bradley's
ability to maintain CARMOL(R) sales and bear the outcome of related pending
litigation and the introduction of new and future competing products, whether
branded, or generic, or comparable, effectively purchase or integrate new
products into its portfolio or effectively react to other risks described from
time to time in Bradley's SEC filings. Further, Bradley cannot predict the
impact on its business of any introduction, or future approvals, of generic or
therapeutically equivalent or comparable versions of its products or of other
competing products. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. Bradley undertakes
no obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.
SOURCE Bradley Pharmaceuticals, Inc.
 back to top
Related links:
http://www.bradpharm.com
http://www.wallstreetwebcasting.com/webcast/rjii04/bdy
CONTACT:
Investors, Anthony Griffo of Bradley
Pharmaceuticals, Inc., +1-973-882-1505, ext. 313
|
